| Literature DB >> 35966346 |
Oliver Abrahamsen1, Eva Balslev1, Mette Christensen2, Flemming Wibrand2, Esben Budtz-Jørgensen3, Estrid Høgdall1.
Abstract
Cancer cells upregulate their metabolism to underlie the increased malignant activity. This requires an increased amount of 'metabolic building materials', for example glucose, amino acids etc., which have the blood circulation as their principal supply lines. Targeting these metabolic supply lines, and thus the availability of metabolic building materials in the blood, therefore carries treatment potential. A central observation is that the malignant alterations comprise great complexity and that compensatory mechanisms exist. Therefore, targeted supply lines should presumably constitute specific patterns to achieve therapeutic effect. The aim of the present study was to investigate if such patterns could be seen to correlate with the development of distant metastases. The study was conducted using a case-cohort design. In total, 64 women diagnosed with breast cancer between January 2011 and December 2015 were included. Among these, 32 had developed distant metastases and 32 had not. From a blood sample drawn at the time of diagnosis, the levels of glucose (HbA1c), glutamine, arginine and cystathionine were measured. Cox regression was applied to investigate the impact of the supply lines of these 'building materials' and specifically the patterns between them on the development of distant metastases. The results demonstrate a significant impact of the investigated metabolic supply lines, centrally in relation to interaction between them and in relation to the impact of the increased cumulated utilization of multiple supply lines simultaneously. In conclusion, the results indicated that the metabolic supply lines may impact clinical outcome, and, in this regard, the results placed a substantial emphasis on the effect of the patterns between these supply lines. Copyright: © Abrahamsen et al.Entities:
Keywords: amino acids; cancer metabolism; clinical outcome; glucose; metastasis
Year: 2022 PMID: 35966346 PMCID: PMC9366742 DOI: 10.3892/ol.2022.13447
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 3.111
Development of distant metastases: Individual impact of the metabolic supply lines (adjusted for tumor histology and age).
| Parameter | Hazard ratio | 95% CI | P-value |
|---|---|---|---|
| HbA1c (glucose) | |||
| HbA1c, mmol/mol | 1.148 | (1.001, 1.317) | 0.048 |
| Age, years | 0.996 | (0.925, 1.073) | 0.916 |
| Tumor histology (ER+ ILC) | 0.536 | (0.137, 2.097) | 0.370 |
| Glutamine | |||
| Glutamine, µmol/l | 0.996 | (0.989, 1.003) | 0.267 |
| Age, years | 1.018 | (0.949, 1.093) | 0.612 |
| Tumor histology (ER+ ILC) | 0.913 | (0.241, 3.456) | 0.894 |
| Arginine | |||
| Arginine, µmol/l | 0.997 | (0.973, 1.021) | 0.802 |
| Age, years | 1.017 | (0.947, 1.092) | 0.641 |
| Tumor histology (ER+ ILC) | 0.815 | (0.230, 2.892) | 0.752 |
| Cystathionine | |||
| Cystathionine, µmol/l | 0.644 | (0.285, 1.454) | 0.289 |
| Age, years | 1.019 | (0.950, 1.093) | 0.602 |
| Tumor histology (ER+ ILC) | 0.717 | (0.197, 2.614) | 0.614 |
ER+ ILC, Estrogen-receptor-positive invasive lobular carcinoma.
Development of distant metastases: Multivariate model including all metabolic supply lines (plus tumor histology and age).
| Parameter | Hazard ratio | 95% CI | P-value |
|---|---|---|---|
| HbA1c, mmol/mol | 1.309 | (1.149, 1.490) | <0.001 |
| Glutamine, µmol/l | 1.000 | (0.992, 1.009) | 0.925 |
| Arginine, µmol/l | 0.968 | (0.927, 1.011) | 0.144 |
| Cystathionine, µmol/l | 0.145 | (0.032, 0.665) | 0.013 |
| Age, years | 0.951 | (0.872, 1.036) | 0.249 |
| Tumor histology (ER+ ILC) | 0.397 | (0.101, 1.567) | 0.187 |
ER+ ILC, Estrogen-receptor-positive invasive lobular carcinoma.
Development of distant metastases: Interaction between the supply lines of glucose and cystathionine.
| Parameter | Hazard ratio | 95% CI | P-value |
|---|---|---|---|
| HbA1c: Cystathionine (high) | 0.906 | (0.738, 1.111) | 0.343 |
| HbA1c: Cystathionine (low) | 1.371 | (1.236, 1.521) | <0.001 |
Table III shows the estimated effect of HbA1c when cystathionine is ‘high’ or ‘low’. Cystathionine was categorized based on the blood concentration into two groups, ‘(high)’ with higher blood concentrations (representing lower utilization) and ‘(low)’ with lower concentrations (representing higher utilization). The effect is significantly different as the P‑value for the interaction term was <0.001.
Development of distant metastases: Index model and variations of the index model.
| Parameter | Hazard ratio | 95% CI | P-value |
|---|---|---|---|
| Index model | |||
| Index value | 1.935 | (1.028, 3.640) | 0.041 |
| Variations of the index model | |||
| Index value >2 points | 3.785 | (0.964, 14.864) | 0.056 |
| Index value >3 points | 44.150 | (10.440, 186.708) | <0.001 |
Figure 1.A hypothetical interpretation of interacting supply lines. Brief schematic representation of a possible interpretation of the basis for the interaction between the supply lines of glucose and cystathionine. ROS, reactive oxygen species.
Figure 2.Metastasis development and HbA1c values. HbA1c values grouped according to whether the patients had developed distant metastases or not. HbA1c, Hemoglobin A1c.